Healthcare Sales & Marketing Network News: LX211

Searching News Database: LX211

HSMN NewsFeed - 19 Oct 2009
Lux Biosciences Completes $50 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital

HSMN NewsFeed - 29 May 2008
Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials
Devices Interventional Cardiology

HSMN NewsFeed - 30 Jan 2008
Lux Granted Fast Track Designation for LX201 for Corneal Transplant Rejection
Biopharmaceuticals Ophthalmology Drug Delivery FDA

HSMN NewsFeed - 7 Aug 2007
Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 31 Jul 2007
EMEA Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation for Lux Biosciences' LX211 for the Treatment of Uveitis
Biopharmaceuticals Ophthalmology Regulatory

HSMN NewsFeed - 15 Jan 2007
Lux Biosciences Receives Orphan Drug Designation from the FDA for Two Ophthalmic Products
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 28 Nov 2006
Lux Biosciences Receives FDA Clearance for LX211 IND
Biopharmaceuticals Ophthalmology FDA

HSMN NewsFeed - 7 Nov 2006
Lux Biosciences Announces Exclusive Worldwide License Agreement with NIH for Late Stage Ophthalmic Product
Devices Licensing Ophthalmology

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.